Mumbai, Nov. 17 -- Lupin announced that the United States Food and Drug Administration (U.S. FDA) has completed a product specific Pre Approval Inspection at its Unit-1 oral solid dosage manufacturing facility in Nagpur. The inspection was carried out from 10 November to 14 November 2025, and concluded with zero 483 observations.

Published by HT Digital Content Services with permission from Capital Market....